O-GlcNAcylation is increased in prostate cancer tissues and enhances malignancy of prostate cancer cells

Gu,Yuchao; Gao,Jiangang; Han,Cuifang; Zhang,Xinling; Liu,Haiyan; Ma,Leina; Sun,Xiaoqing; Yu,Wengong

doi:10.3892/mmr.2014.2269

O-GlcNAcylation is increased in prostate cancer tissues and enhances malignancy of prostate cancer cells

Authors:
- Yuchao Gu
- Jiangang Gao
- Cuifang Han
- Xinling Zhang
- Haiyan Liu
- Leina Ma
- Xiaoqing Sun
- Wengong Yu
View Affiliations

Affiliations: Key Laboratory of Marine Drugs, Chinese Ministry of Education, Key Laboratory of Glycoscience and Glycotechnology of Shandong Province, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, P.R. China, Department of Urology Surgery, Qingdao Municipal Hospital, Qingdao 266011, P.R. China
Published online on: May 26, 2014 https://doi.org/10.3892/mmr.2014.2269
Pages: 897-904

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

O-GlcNAc is an O-linked ?-N-acetylglucosamine moiety attached to the side-chain hydroxyl of a serine or threonine residue in numerous cytoplasmic and nuclear proteins. In this study, we detected the level of O-GlcNAc in prostate, liver and pancreatic cancer tissues, and found that the global O-GlcNAc modification also known as O-GlcNAcylation, is specifically increased in prostate cancer tissues compared to corresponding adjacent tissues. In addition, we found that global O-GlcNAcylation is increased in prostate cancer cells and not in benign prostatic hyperplasia (BPH) epithelial cells. O-GlcNAc enhanced the anchorage-independent growth and the migratory/invasive ability of prostate cancer cells. More importantly, we provide here, for the first time to the best of our knowledge, direct evidence that increased O-GlcNAcylation induces malignant transformation of nontumorigenic (BPH) cells. Furthermore, our study suggested that inhibiting the formation of the E-cadherin/catenin/cytoskeleton complex may underly the O-GlcNAc-induced prostate cancer progression. Overall, these findings indicated that O-GlcNAcylation is increased in prostate, but not in liver and pancreatic cancer tissues, and that O-GlcNAc can enhance the malignancy of prostate cancer cells.

View Figures

View References

1	Banerjee PS, Hart GW and Cho JW: Chemical approaches to study O-GlcNAcylation. Chem Soc Rev. 42:4345–4357. 2013. View Article : Google Scholar : PubMed/NCBI
2	Marshall S, Bacote V and Traxinger RR: Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem. 266:4706–4712. 1991.
3	Kreppel LK and Hart GW: Regulation of a cytosolic and nuclear O-GlcNAc transferase. Role of the tetratricopeptide repeats. J Biol Chem. 274:32015–32022. 1999. View Article : Google Scholar : PubMed/NCBI
4	Park SY, Ryu J and Lee W: O-GlcNAc modification on IRS-1 and Akt2 by PUGNAc inhibits their phosphorylation and induces insulin resistance in rat primary adipocytes. Exp Mol Med. 37:220–229. 2005. View Article : Google Scholar : PubMed/NCBI
5	Yang X, Ongusaha PP, Miles PD, et al: Phosphoinositide signalling links O-GlcNAc transferase to insulin resistance. Nature. 451:964–969. 2008. View Article : Google Scholar : PubMed/NCBI
6	Buse MG: Hexosamines, insulin resistance, and the complications of diabetes: current status. Am J Physiol Endocrinol Metab. 290:E1–E8. 2006. View Article : Google Scholar : PubMed/NCBI
7	Liu F, Iqbal K, Grundke-Iqbal I, Hart GW and Gong CX: O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer’s disease. Proc Natl Acad Sci USA. 101:10804–10809. 2004.PubMed/NCBI
8	Slawson C and Hart GW: O-GlcNAc signalling: implications for cancer cell biology. Nat Rev Cancer. 11:678–684. 2011. View Article : Google Scholar : PubMed/NCBI
9	Warburg O: On the origin of cancer cells. Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
10	Pecqueur C, Oliver L, Oizel K, Lalier L and Vallette FM: Targeting metabolism to induce cell death in cancer cells and cancer stem cells. Int J Cell Biol. 2013:8059752013. View Article : Google Scholar : PubMed/NCBI
11	Mi W, Gu Y, Han C, et al: O-GlcNAcylation is a novel regulator of lung and colon cancer malignancy. Biochim Biophys Acta. 1812:514–519. 2011. View Article : Google Scholar : PubMed/NCBI
12	Gu Y, Mi W, Ge Y, et al: GlcNAcylation plays an essential role in breast cancer metastasis. Cancer Res. 70:6344–6351. 2010. View Article : Google Scholar : PubMed/NCBI
13	Lynch TP, Ferrer CM, Jackson SR, Shahriari KS, Vosseller K and Reginato MJ: Critical role of O-linked β-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis. J Biol Chem. 287:11070–11081. 2012.
14	Caldwell SA, Jackson SR, Shahriari KS, et al: Nutrient sensor O-GlcNAc transferase regulates breast cancer tumorigenesis through targeting of the oncogenic transcription factor FoxM1. Oncogene. 29:2831–2842. 2010. View Article : Google Scholar
15	Ma Z, Vocadlo DJ and Vosseller K: Hyper-O-GlcNAcylation is anti-apoptotic and maintains constitutive NF-κB activity in pancreatic cancer cells. J Biol Chem. 288:15121–15130. 2013.PubMed/NCBI
16	Fromowitz FB, Viola MV, Chao S, et al: ras p21 expression in the progression of breast cancer. Hum Pathol. 18:1268–1275. 1987. View Article : Google Scholar : PubMed/NCBI
17	Qin JM, Fu XY, Li SJ, et al: Gene and protein expressions of p28GANK in rat with liver regeneration. World J Gastroenterol. 9:2523–2527. 2003.PubMed/NCBI
18	Yuzwa SA, Macauley MS, Heinonen JE, et al: A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. Nat Chem Biol. 4:483–490. 2008. View Article : Google Scholar : PubMed/NCBI
19	Gu Y, Zhang J, Mi W, et al: Silencing of GM3 synthase suppresses lung metastasis of murine breast cancer cells. Breast Cancer Res. 10:R12008. View Article : Google Scholar : PubMed/NCBI
20	Zhu W, Leber B and Andrews DW: Cytoplasmic O-glycosylation prevents cell surface transport of E-cadherin during apoptosis. Embo J. 20:5999–6007. 2001. View Article : Google Scholar : PubMed/NCBI
21	Love DC, Kochan J, Cathey RL, Shin SH and Hanover JA: Mitochondrial and nucleocytoplasmic targeting of O-linked GlcNAc transferase. J Cell Sci. 116:647–654. 2003. View Article : Google Scholar : PubMed/NCBI
22	Itkonen HM, Minner S, Guldvik IJ, et al: O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells. Cancer Res. 73:5277–5287. 2013. View Article : Google Scholar : PubMed/NCBI
23	Shin SH, Love DC and Hanover JA: Elevated O-GlcNAc-dependent signaling through inducible mOGT expression selectively triggers apoptosis. Amino Acids. 40:885–893. 2011. View Article : Google Scholar : PubMed/NCBI
24	Hirohashi S: Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol. 153:333–339. 1998. View Article : Google Scholar : PubMed/NCBI
25	Park SY, Kim HS, Kim NH, et al: Snail1 is stabilized by O-GlcNAc modification in hyperglycaemic condition. EMBO J. 29:3787–3796. 2010. View Article : Google Scholar : PubMed/NCBI
26	Pokutta S and Weis WI: Structure and mechanism of cadherins and catenins in cell-cell contacts. Annu Rev Cell Dev Biol. 23:237–261. 2007. View Article : Google Scholar : PubMed/NCBI
27	Shi Y, Tomic J, Wen F, et al: Aberrant O-GlcNAcylation characterizes chronic lymphocytic leukemia. Leukemia. 24:1588–1598. 2010. View Article : Google Scholar : PubMed/NCBI
28	Shen DL, Gloster TM, Yuzwa SA and Vocadlo DJ: Insights into O-linked N-acetylglucosamine ([0-9]O-GlcNAc) processing and dynamics through kinetic analysis of O-GlcNAc transferase and O-GlcNAcase activity on protein substrates. J Biol Chem. 287:15395–15408. 2012.
29	Zhu Q, Zhou L, Yang Z, et al: O-GlcNAcylation plays a role in tumor recurrence of hepatocellular carcinoma following liver transplantation. Med Oncol. 29:985–993. 2012. View Article : Google Scholar : PubMed/NCBI
30	Hayward SW, Dahiya R, Cunha GR, Bartek J, Deshpande N and Narayan P: Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1. In Vitro Cell Dev Biol Anim. 31:14–24. 1995. View Article : Google Scholar : PubMed/NCBI
31	Hayward SW, Wang Y, Cao M, et al: Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Res. 61:8135–8142. 2001.PubMed/NCBI
32	Webber MM, Quader ST, Kleinman HK, et al: Human cell lines as an in vitro/in vivo model for prostate carcinogenesis and progression. Prostate. 47:1–13. 2001. View Article : Google Scholar : PubMed/NCBI